海外MNC 抢滩FGF21 靶点,推荐国内投资机会MASH 是基于较大患者基数、明确临床需求与商业化验证形成的确定性赛道。根据Frost & Sullivan 预测,2030 年中国及全球的MASH 患病人数将分别达到0.56亿人和4.9 亿人。MASH 创新管线众多,FGF21 能够调控脂代谢以及阻止纤维化,全球药企竞相布局。海外研发格局看,目前依鲁西夫明、Pegozafermin、...
Source Link海外MNC 抢滩FGF21 靶点,推荐国内投资机会MASH 是基于较大患者基数、明确临床需求与商业化验证形成的确定性赛道。根据Frost & Sullivan 预测,2030 年中国及全球的MASH 患病人数将分别达到0.56亿人和4.9 亿人。MASH 创新管线众多,FGF21 能够调控脂代谢以及阻止纤维化,全球药企竞相布局。海外研发格局看,目前依鲁西夫明、Pegozafermin、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.